Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Subscribe

Logo for

J. Biol. Chem. 275 (25): 19159-19166

© 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

Mildly Oxidized Low Density Lipoprotein Rapidly Stimulates via Activation of the Lysophosphatidic Acid Receptor Src Family and Syk Tyrosine Kinases and Ca2+ Influx in Human Platelets*

Petra MaschbergerDagger , Markus BauerDagger , Jutta Baumann-SiemonsDagger , Konrad J. ZanglDagger , Emil V. NegrescuDagger §, Armin J. Reininger||, and Wolfgang SiessDagger **

From the Dagger  Institut für Prophylaxe und Epidemiologie der Kreislaufkrankheiten, Universität München, Pettenkoferstrasse P, D-80336 München, Germany and  Institut für Anatomie, Technische Universität München, Biedersteiner Strasse 29, D-80802 München, Germany

In contrast to native low density lipoprotein (LDL), mildly oxidized LDL (mox-LDL) induced platelet shape change and stimulated during shape change the tyrosine phosphorylation of specific proteins including Syk; the translocation of Src, Fyn, and Syk to the cytoskeleton; and the increase of cytosolic Ca2+ due to mainly Ca2+ entry. The stimulation of these early signal pathways by mox-LDL was inhibited by desensitization of the lysophosphatidic acid (LPA) receptor and specific LPA receptor antagonists, was independent of the alpha IIbbeta 3-integrin, and was mimicked by LPA. Stimulation of tyrosine phosphorylation and Syk activation were independent of the increase of cytosolic Ca2+ and were suppressed by genistein and two specific inhibitors of the Src family tyrosine kinases, PP1 and PD173956. In contrast to PP1 and PD 173956, genistein prevented shape change by mox-LDL. The results indicate that mox-LDL, through activation of the LPA receptor, stimulates two separate early signal pathways, (a) Src family and Syk tyrosine kinases, and (b) Ca2+ entry. The activation of these early signaling pathways by mox-LDL probably plays a role in platelet responses subsequent to shape change. The inhibition of mox-LDL-induced platelet activation by LPA receptor antagonists or dietary isoflavonoids such as genistein could have implications in the prevention and therapy of cardiovascular diseases.


* This work was supported by the Ernst und Berta Grimmke-Stiftung, Deutsche Forschungsgemeinschaft Grants Si 274 6-1 and GRK 438, and the August-Lenz-Stiftung. This work is submitted in partial fulfillment of thesis requirements for P. M., M. B., J. B.-S., and K. J. Z. at the University of Munich.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ Present address: Dept. of Molecular Cardiology, Joseph J. Jacobs Center for Thrombosis and Vascular Biology, The Cleveland Clinic Foundation, Cleveland, OH 44195.

|| Present address: The Scripps Research Institute, Department of Molecular and Experimental Medicine, La Jolla, CA 92037.

** To whom correspondence should be addressed: Institut für Prophylaxe und Epidemiologie der Kreislaufkrankheiten, Klinikum Innenstadt, Universität München, Pettenkoferstr. 9, D-80336 München, Germany. Tel.: 49-89-5160-4380; Fax: 49-89-5160-4382; E-mail: wolfgang.siess@klp.med.uni-muenchen.de.


Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Group VIA Phospholipase A2 Mediates Enhanced Macrophage Migration in Diabetes Mellitus by Increasing Expression of Nicotinamide Adenine Dinucleotide Phosphate Oxidase 4.
C. Tan, R. Day, S. Bao, J. Turk, and Q. D. Zhao (2014)
Arterioscler Thromb Vasc Biol 34, 768-778
   Abstract »    Full Text »    PDF »
Vav guanine nucleotide exchange factors link hyperlipidemia and a prothrombotic state.
K. Chen, W. Li, J. Major, S. O. Rahaman, M. Febbraio, and R. L. Silverstein (2011)
Blood 117, 5744-5750
   Abstract »    Full Text »    PDF »
GPR92/LPA5 lysophosphatidate receptor mediates megakaryocytic cell shape change induced by human atherosclerotic plaques.
A. L. Khandoga, D. Pandey, U. Welsch, R. Brandl, and W. Siess (2011)
Cardiovasc Res 90, 157-164
   Abstract »    Full Text »    PDF »
Regulation of Platelet Function by Class B Scavenger Receptors in Hyperlipidemia.
A. Zimman and E. A. Podrez (2010)
Arterioscler Thromb Vasc Biol 30, 2350-2356
   Abstract »    Full Text »    PDF »
Unique Ligand Selectivity of the GPR92/LPA5 Lysophosphatidate Receptor Indicates Role in Human Platelet Activation.
J. R. Williams, A. L. Khandoga, P. Goyal, J. I. Fells, D. H. Perygin, W. Siess, A. L. Parrill, G. Tigyi, and Y. Fujiwara (2009)
J. Biol. Chem. 284, 17304-17319
   Abstract »    Full Text »    PDF »
Sphingosine-1-phosphate and modulation of vascular tone.
J. Igarashi and T. Michel (2009)
Cardiovasc Res 82, 212-220
   Abstract »    Full Text »    PDF »
Autotaxin/Lysopholipase D and Lysophosphatidic Acid Regulate Murine Hemostasis and Thrombosis.
Z. Pamuklar, L. Federico, S. Liu, M. Umezu-Goto, A. Dong, M. Panchatcharam, Z. Fulerson, E. Berdyshev, V. Natarajan, X. Fang, et al. (2009)
J. Biol. Chem. 284, 7385-7394
   Abstract »    Full Text »    PDF »
Platelet Activation by Low Concentrations of Intact Oxidized LDL Particles Involves the PAF Receptor.
R. Chen, X. Chen, R. G. Salomon, and T. M. McIntyre (2009)
Arterioscler Thromb Vasc Biol 29, 363-371
   Abstract »    Full Text »    PDF »
A Specific CD36-Dependent Signaling Pathway Is Required for Platelet Activation by Oxidized Low-Density Lipoprotein.
K. Chen, M. Febbraio, W. Li, and R. L. Silverstein (2008)
Circ. Res. 102, 1512-1519
   Abstract »    Full Text »    PDF »
Platelet lipoprotein interplay: trigger of foam cell formation and driver of atherosclerosis.
D. Siegel-Axel, K. Daub, P. Seizer, S. Lindemann, and M. Gawaz (2008)
Cardiovasc Res 78, 8-17
   Abstract »    Full Text »    PDF »
Platelet Activation by Oxidized Low Density Lipoprotein Is Mediated by Cd36 and Scavenger Receptor-A.
S. J.A. Korporaal, M. Van Eck, J. Adelmeijer, M. Ijsseldijk, R. Out, T. Lisman, P. J. Lenting, T. J.C. Van Berkel, and J.-W. N. Akkerman (2007)
Arterioscler Thromb Vasc Biol 27, 2476-2483
   Abstract »    Full Text »    PDF »
Effect of Oxidation on the Platelet-Activating Properties of Low-Density Lipoprotein.
S. J.A. Korporaal, G. Gorter, H. J.M. van Rijn, and J.-W. N. Akkerman (2005)
Arterioscler Thromb Vasc Biol 25, 867-872
   Abstract »    Full Text »    PDF »
Lysophospholipids increase ICAM-1 expression in HUVEC through a Gi- and NF-{kappa}B-dependent mechanism.
H. Lee, C. I. Lin, J.-J. Liao, Y.-W. Lee, H. Y. Yang, C.-Y. Lee, H.-Y. Hsu, and H. L. Wu (2004)
Am J Physiol Cell Physiol 287, C1657-C1666
   Abstract »    Full Text »    PDF »
Cbl-mediated Degradation of Lyn and Fyn Induced by Constitutive Fibroblast Growth Factor Receptor-2 Activation Supports Osteoblast Differentiation.
K. Kaabeche, J. Lemonnier, S. Le Mee, J. Caverzasio, and P. J. Marie (2004)
J. Biol. Chem. 279, 36259-36267
   Abstract »    Full Text »    PDF »
LDL oxidized by hypochlorous acid causes irreversible platelet aggregation when combined with low levels of ADP, thrombin, epinephrine, or macrophage-derived chemokine (CCL22).
L. G. Coleman Jr, R. K. Polanowska-Grabowska, M. Marcinkiewicz, and A. R. L. Gear (2004)
Blood 104, 380-389
   Abstract »    Full Text »    PDF »
Modification of LDL with human secretory phospholipase A2 or sphingomyelinase promotes its arachidonic acid-releasing propensity.
J. Oestvang, D. Bonnefont-Rousselot, E. Ninio, J. K. Hakala, B. Johansen, and M. W. Anthonsen (2004)
J. Lipid Res. 45, 831-838
   Abstract »    Full Text »    PDF »
The plaque lipid lysophosphatidic acid stimulates platelet activation and platelet-monocyte aggregate formation in whole blood: involvement of P2Y1 and P2Y12 receptors.
N. Haseruck, W. Erl, D. Pandey, G. Tigyi, P. Ohlmann, C. Ravanat, C. Gachet, and W. Siess (2004)
Blood 103, 2585-2592
   Abstract »    Full Text »    PDF »
Lysophosphatidic Acid (LPA) in Malignant Ascites Stimulates Motility of Human Pancreatic Cancer Cells through LPA1.
T. Yamada, K. Sato, M. Komachi, E. Malchinkhuu, M. Tobo, T. Kimura, A. Kuwabara, Y. Yanagita, T. Ikeya, Y. Tanahashi, et al. (2004)
J. Biol. Chem. 279, 6595-6605
   Abstract »    Full Text »    PDF »
Ki16425, a Subtype-Selective Antagonist for EDG-Family Lysophosphatidic Acid Receptors.
H. Ohta, K. Sato, N. Murata, A. Damirin, E. Malchinkhuu, J. Kon, T. Kimura, M. Tobo, Y. Yamazaki, T. Watanabe, et al. (2003)
Mol. Pharmacol. 64, 994-1005
   Abstract »    Full Text »    PDF »
Subtype-Selective Antagonists of Lysophosphatidic Acid Receptors Inhibit Platelet Activation Triggered by the Lipid Core of Atherosclerotic Plaques.
E. Rother, R. Brandl, D. L. Baker, P. Goyal, H. Gebhard, G. Tigyi, and W. Siess (2003)
Circulation 108, 741-747
   Abstract »    Full Text »    PDF »
LPA is a novel lipid regulator of mesangial cell hexokinase activity and HKII isoform expression.
P. E. Coy, N. Taneja, I. Lee, C. Hecquet, J. M. Bryson, and R. B. Robey (2002)
Am J Physiol Renal Physiol 283, F271-F279
   Abstract »    Full Text »    PDF »
Upregulation of CD40 and CD40 Ligand (CD154) in Patients With Moderate Hypercholesterolemia.
C. D. Garlichs, S. John, A. Schmei{beta}er, S. Eskafi, C. Stumpf, M. Karl, M. Goppelt-Struebe, R. Schmieder, and W. G. Daniel (2001)
Circulation 104, 2395-2400
   Abstract »    Full Text »    PDF »
Hematopoietic reconstitution of SLP-76 corrects hemostasis and platelet signaling through alpha IIbbeta 3 and collagen receptors.
B. A. Judd, P. S. Myung, L. Leng, A. Obergfell, W. S. Pear, S. J. Shattil, and G. A. Koretzky (2000)
PNAS 97, 12056-12061
   Abstract »    Full Text »    PDF »

To Advertise     Find Products


Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882